Lung adenocarcinoma is one of the leading causes of mortality among cancer patients
worldwide and chronic obstructive pulmonary disease (COPD) is also high in death statistics.
In addition, patients with chronic obstructive pulmonary disease (COPD) have a high
risk of developing primary lung cancer. Prevention, risk estimation and a non-invasive diagnostics
are essential to decrease COPD and lung cancer mortality. Therefore, better and more
accurate molecular diagnostic markers (biomarkers) are needed for the early differential diagnosis
of these lung diseases to help clinicians make better therapeutic decisions. This review
focuses on recently discovered adenocarcinoma and COPD biomarkers at the proteome and
glycome level. In the first part, the protein markers are summarized, while the second part is
focused on glycan markers. Their use to differentiate between chronic inflammation (COPD)
and malignant (adenocarcinoma) diseases is discussed in detail.
Keywords: lung cancer, lung adenocarcinoma, COPD, molecular markers, proteomics, glycomics.
Rights & PermissionsPrintExport